CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 21, 2014--
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that it has
commenced an underwritten public offering of 2,000,000 shares of its
common stock. All of the shares in the offering are to be sold by Agios.
Agios intends to grant the underwriters a 30-day option to purchase up
to an additional 300,000 shares of common stock sold in the offering.
The proceeds of the offering are expected to be used to fund the
company’s clinical and research development activities. The offering is
subject to market and other conditions, and there can be no assurance as
to whether or when the offering may be completed.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint
book-running managers for the offering. Cowen and Company, LLC and
Leerink Partners LLC are serving as co-managers.
A registration statement on Form S-1 relating to the securities proposed
to be sold in this offering has been filed with the Securities and
Exchange Commission but has not yet become effective. The securities may
not be sold nor may offers to buy be accepted prior to the time that the
registration statement becomes effective.
The securities described in this release are being offered only by means
of a prospectus. A copy of the preliminary prospectus can be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, telephone:
866-803-9204; or Goldman, Sachs, & Co., Attn: Prospectus Department, 200
West Street, New York, NY 10282, telephone: 866-471-2526, facsimile:
212-902-9316, e-mail: firstname.lastname@example.org.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel
drugs to treat cancer and inborn errors of metabolism, or IEMs, which
are rare genetic metabolic diseases, through scientific leadership in
the field of cellular metabolism. In addition to an active research and
discovery pipeline across both therapeutic areas, Agios has multiple
first-in-class lead product candidates in cancer metabolism and IEMs in
clinical and/or preclinical development.
Source: Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Lora Pike, Senior Director, Investor
Relations and Public Relations